Interleukin 1 Receptor-Associated Kinase 4 is Overexpressed in Hidradenitis Suppurativa Skin and Correlates with Inflammatory Biomarkers.

Hidradenitis suppurativa IL-1R/TLR IRAK4 KT-474 cytokines

Journal

The Journal of investigative dermatology
ISSN: 1523-1747
Titre abrégé: J Invest Dermatol
Pays: United States
ID NLM: 0426720

Informations de publication

Date de publication:
17 Jul 2024
Historique:
received: 27 02 2024
revised: 19 04 2024
accepted: 30 04 2024
medline: 1 8 2024
pubmed: 1 8 2024
entrez: 31 7 2024
Statut: aheadofprint

Résumé

Hidradenitis suppurativa (HS) is a chronic inflammatory disease manifesting as painful dermal nodules, abscesses, and tunnels. Activation of the IL-1R/toll-like receptor (TLR) pathway is strongly implicated in the pathogenesis of HS; thus, the role of a key signaling node, IL-1R-associated kinase 4 (IRAK4), was investigated in a noninterventional study (NCT04440410) that enrolled 30 patients with HS. IRAK4 expression was evaluated in blood and lesional, perilesional, and nonlesional skin biopsies. Peripheral blood mononuclear cells (PBMCs) expressed IRAK4, with significantly higher levels in monocytes (P ≤ 0.0001). Ex vivo treatment of PBMCs with KT-474, a targeted degrader of IRAK4, robustly decreased IRAK4 in all immune cell types from healthy volunteers and patients with HS. Ex vivo treatment of TLR-stimulated healthy donor monocytes with KT-474 decreased IRAK4 protein levels and inhibited inflammatory cytokine production. In HS skin samples, IRAK4 protein levels were significantly higher in lesional versus nonlesional tissue (P ≤ 0.0001), and IRAK4-positive immune infiltrate increased with greater disease severity. Multiple inflammatory mediators were upregulated in HS lesional skin, correlating with IRAK4 overexpression. These data confirm the significance of the IL-1R/TLR pathway in the pathogenesis of HS and provide support for ongoing clinical studies evaluating KT-474 in the treatment of HS.

Identifiants

pubmed: 39084489
pii: S0022-202X(24)01899-2
doi: 10.1016/j.jid.2024.04.035
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.

Auteurs

Alice McDonald (A)

Kymera Therapeutics, Inc., Watertown, MA, USA. Electronic address: alice@kymeratx.com.

Rahul Karnik (R)

Kymera Therapeutics, Inc., Watertown, MA, USA.

Veronica Campbell (V)

Kymera Therapeutics, Inc., Watertown, MA, USA.

Jeff Davis (J)

Kymera Therapeutics, Inc., Watertown, MA, USA.

Sara Chavoshi (S)

GSK Canada, Mississauga, ON, Canada.

Anthony Slavin (A)

Kymera Therapeutics, Inc., Watertown, MA, USA.

Kirti Sharma (K)

Kymera Therapeutics, Inc., Watertown, MA, USA.

Jared Gollob (J)

Kymera Therapeutics, Inc., Watertown, MA, USA.

Afsaneh Alavi (A)

Mayo Clinic Rochester, Rochester, MN, USA.

Classifications MeSH